Meet Gattefossé at AAPS PharmSci 360
Visit Gattefossé at AAPS PharmSci 360 to learn how our expert support helps you overcome challenges at every stage of development.
We're ready to discuss how our lipid-based solutions can increase oral bioavailability, improve topical drug delivery, and help you develop specialized rectal and vaginal products.
Want to secure time with our team for detailed discussions? Fill out the form below to schedule a meeting.
Request a Meeting with Our Team
Learn About Our New Manufacturing Site in Lufkin, TX
Bookmark Our Featured Posters
(M0930-02-13) Exploring Different Manufacturing Techniques for Introducing Pelletised Gelucires® in Tablet Formulations
Monday, November 10, 2025 | 9:30 AM - 10:30 AM CT
This study explored practical methods to incorporate pelletized Gelucire® excipients into tablet formulations using fenofibrate as a model drug. Both wet granulation and fluid bed granulation successfully produced robust, fast-dissolving tablets, with Gelucire® 59/14 improving drug dissolution (>75% in 45 min) and demonstrating a scalable, industry-ready approach for enhancing solubility in solid dosage forms.
(M1130-02-11) Investigating the Impact of Matrix Porosity on the Stability of Compritol®888 ATO Containing Extended-Release Tablets Formulated Using Hot Melt Process
Monday, November 10, 2025 | 11:30 AM - 12:30 PM CT
This study examined how matrix porosity affects the stability of Compritol® 888 ATO–based extended-release tablets made by hot melt granulation. Results showed that the choice of diluent—particularly the use of porous versus non-porous fillers—influences long-term release stability and consistency.
(M1330-07-41) Impact of Gastric Phase Simulation on the In Vitro Lipolysis of Lipid-Based Formulations Containing Ticagrelor or Fenofibrate
Monday, November 10, 2025 | 1:30 PM - 2:30 PM CT
This study evaluated how incorporating a gastric phase into in vitro lipolysis protocols affects drug solubilization for two poorly soluble APIs—ticagrelor (BCS IV) and fenofibrate (BCS II)—formulated with various Gattefossé excipients (Labrasol® ALF, Labrafac™ MC60, Transcutol® HP, Maisine® CC, Capryol® 90, Tween® 80). The results show that including a gastric phase substantially improved solubilization across formulations compared to an intestinal-only model, suggesting that gastric conditions promote more favorable colloidal structures.
(T1030-02-08) Rethinking In Vitro Testing: Using Biorelevant Media for Dispersion/Dissolution Testing for Lipid-Based Drug Delivery
Tuesday, November 11, 2025 | 10:30 AM - 11:30 AM CT
This study compared traditional dissolution media with biorelevant media for evaluating lipid-based formulations of two poorly soluble drugs. Results showed that biorelevant media better predict in vivo performance, as several formulations that failed to disperse in water showed excellent solubilization and bioavailability under biorelevant conditions—highlighting the importance of using physiologically relevant testing for LBFs.
(W0930-09-56) Assessing the Performance of Lipids as Surfactants to Enhance the Release Profile of a Model BCS Class IV Compound from Amorphous Solid Dispersions (ASDs)
Wednesday, November 12, 2025 | 9:30 AM - 10:30 AM CT
This study evaluated lipid-based excipients (Gelucire® and Labrafil®) as surfactants in hot-melt extruded amorphous solid dispersions of Anacetrapib, a poorly soluble BCS Class IV drug. Incorporating lipids like Gelucire® 44/14 and 48/16 enhanced drug solubilization 3- to 5-fold compared to traditional ASDs, demonstrating that lipids can improve dissolution performance and may further enhance in vivo absorption.